Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Chakradhara Rao Satyanarayana, Uppugunduri"'
Autor:
Khalil Ben Hassine, Tiago Nava, Yves Théoret, Christa E. Nath, Youssef Daali, Nastya Kassir, Victor Lewis, Robbert G. M. Bredius, Peter J. Shaw, Henrique Bittencourt, Maja Krajinovic, Chakradhara Rao Satyanarayana Uppugunduri, Marc Ansari
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 9, Pp 1043-1056 (2021)
Abstract Busulfan (Bu) is a common component of conditioning regimens before hematopoietic stem cell transplantation (HSCT) and is known for high interpatient pharmacokinetic (PK) variability. This study aimed to develop and externally validate a mul
Externí odkaz:
https://doaj.org/article/4a2a660863bf4f659cde9d7b20f139cd
Publikováno v:
Archives of Medicine and Health Sciences, Vol 5, Iss 1, Pp 115-122 (2017)
Pediatric pharmacokinetics (PK) and pharmacodynamics (PD) differ from adults in multiple aspects. The extrapolation of PK/PD data from adults to children is not always simple because children are not small adults. Differential development of metaboli
Externí odkaz:
https://doaj.org/article/63d8d135966441eab2858ec6fb507324
Autor:
Claire Seydoux, Chakradhara Rao Satyanarayana Uppugunduri, Michael Medinger, Tiago Nava, Joerg Halter, Dominik Heim, Yves Chalandon, Urs Schanz, Gayathri Nair, Nathan Cantoni, Jakob R. Passweg, Marc Ansari
Publikováno v:
Bone Marrow Transplantation.
Busulfan (Bu) combined with cyclophosphamide (Cy) is commonly used as a myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT). There is inter-individual variability of Bu pharmacokinetics (PK) and hence in to
Autor:
Sunitha Kodidela, Patchava Dorababu, Dimpal N Thakkar, Biswajit Dubashi, Rajan Sundaram, Niveditha Muralidharan, Ravi Prasad Nidanapu, Anil Aribandi, Suresh Chandra Pradhan, Chakradhara Rao Satyanarayana Uppugunduri
Publikováno v:
Genes, Vol 11, Iss 594, p 594 (2020)
Genetic variants influencing the pharmacokinetics and/or pharmacodynamics of the chemotherapeutic drugs used in Acute Lymphoblastic Leukemia (ALL) therapy often contribute to the occurrence of treatment related toxicity (TRT). In this study, we explo
Autor:
Sunitha, Kodidela, Patchava, Dorababu, Dimpal N, Thakkar, Biswajit, Dubashi, Rajan, Sundaram, Niveditha, Muralidharan, Ravi Prasad, Nidanapu, Anil, Aribandi, Suresh Chandra, Pradhan, Chakradhara Rao Satyanarayana, Uppugunduri
Publikováno v:
Genes
Genetic variants influencing the pharmacokinetics and/or pharmacodynamics of the chemotherapeutic drugs used in Acute Lymphoblastic Leukemia (ALL) therapy often contribute to the occurrence of treatment related toxicity (TRT). In this study, we explo
Autor:
Krishnamoorthy Rajagopal, Deepak Gopal Shewade, Rajan Sundaram, Adithan Chandrasekaran, Chakradhara Rao Satyanarayana Uppugunduri, Anichavezhi Devendran
Publikováno v:
Molecular Biology International
CYP2C19 is a polymorphic enzyme involved in the metabolism of clinically important drugs. Genotype-phenotype association studies of CYP2C19 have reported wide ranges in the metabolic ratios of its substrates. These discrepancies could be attributed t
Publikováno v:
Medical hypotheses. 76(2)